GlassScriptPhysician profile
Diana A Hussain
NPI 1285776971
$6,854.20
in general payments reported to CMS, 2019-2025
21 companies · $706 in 2025
The $706 reported for 2025 was more than what 84% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $460 · 2021: $2,102 · 2022: $926 · 2023: $1,454 · 2024: $594 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,040 · Travel and Lodging: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,039.80 |
| Travel and Lodging | $715.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,524.97 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,392.16 | 2021 | |
| Medtronic, INC. | $1,164.70 | 2023-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Amgen INC. | $545.97 | 2019-2022 | |
| Pfizer INC. | $467.55 | 2019-2025 | |
| Allergan, INC. | $275.56 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $269.02 | 2022 | |
| Novartis Pharmaceuticals Corporation | $175.83 | 2019-2021 | |
| Lilly USA, LLC | $171.56 | 2019-2022 | |
| Axsome Therapeutics, INC. | $146.87 | 2025 | Symbravo |
| Merz Pharmaceuticals, LLC | $115.38 | 2021-2025 | Xeomin |
| Janssen Pharmaceuticals, INC | $99.94 | 2019 | |
| Mdd US Operations, LLC | $90.13 | 2019-2020 | |
| Bausch Health US, LLC | $83.29 | 2019 | |
| Merz North America, INC. | $70.65 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microtransponder, INC. | $56.96 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $48.89 | 2019-2021 | |
| Boston Scientific Corporation | $48.53 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Upsher-Smith Laboratories LLC | $48.10 | 2021-2022 | |
| Biotronik Nro, INC. | $41.49 | 2025 | Prospera |
| Metacel Pharmaceuticals LLC | $16.65 | 2023 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.